Ac­celeron scraps dalanter­cept af­ter it flunks a PhII test for kid­ney can­cer

Ac­celeron will not be get­ting any help from dalanter­cept as it works to build con­fi­dence in its pipeline.

The Cam­bridge, MA-based biotech says their an­gio­gen­e­sis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER